Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01855867 · ClinicalTrials.gov registry record · Phase 4
HIV Non-Occupational Post-Exposure Prophylaxis
A Phase 4 study of Human Immunodeficiency Virus, sponsored by Kenneth H. Mayer, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT01855867 is a Phase 4 study of Human Immunodeficiency Virus that has completed, run by Kenneth H. Mayer, MD. The registered enrollment target is 100 participants, below the 181-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01855867, a Phase 4 study of Human Immunodeficiency Virus, has completed, sponsored by Kenneth H. Mayer, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if an anti-HIV medication known as Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir DF) is safe, tolerable and acceptable when taken for 28 days, once a day after a possible, sexual, exposure to the Human Immune Deficiency Virus (HIV).
Conditions Studied
Interventions
- DRUG Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Study Locations (1)
Massachusetts
- Fenway Community Health - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01855867
The ClinicalTrials.gov registry entry for NCT01855867 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (45% lower). The listed sponsor is Kenneth H. Mayer, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) is the first listed.
NCT01855867 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01855867 about?
NCT01855867 is a clinical study titled "HIV Non-Occupational Post-Exposure Prophylaxis". The purpose of this study is to see if an anti-HIV medication known as Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir DF) is safe, tolerable and acceptable when taken for 28 days, once a day after a possible, sexual, exposure to the Human Immune Deficiency Virus (HIV).
What is the current status of trial NCT01855867?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2013-05. Estimated completion is 2016-04.
What conditions does trial NCT01855867 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT01855867?
The interventions under investigation include: Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) (DRUG).
Who is sponsoring clinical trial NCT01855867?
This trial is sponsored by Kenneth H. Mayer, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01855867 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose Naltrexone for Pain in Patients With HIV
RECRUITING · Phase 4
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Post-Exposure Prophylaxis in Health Care Workers
COMPLETED · Phase 4
-
Biomarkers for Event-driven PrEP Adherence
COMPLETED · Phase 4
-
Switching Undetectables to Selzentry
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.